Skip to main content
Have a personal or library account? Click to login
Role of alpha and gamma Klotho genes in the development of differentiated thyroid carcinoma on top of goiter Cover

Role of alpha and gamma Klotho genes in the development of differentiated thyroid carcinoma on top of goiter

Open Access
|Sep 2023

Figures & Tables

Table 1:

Demographic and laboratory parameters of the studied groups.

ParameterGroupp value
Case (DTC) (n = 40)Control (goiter) (n = 40)
Age (years)41.08 ± 11.341.08 ± 11.3*1.000
  Sex:
  Male9 (22.5%)9 (22.5%)**1.000
  Female31 (77.5%)31 (77.5%)
BMI (kg/m2)30.30 ± 6.233.80 ± 5.4*0.008
Serum total T3 (μg/dL)1.27 ± 0.41.23 ± 0.3*0.456
Serum total T4 (μg/dL)7.24 (6.50–8.25)7.85 (6.30–8.85)***0.528
Serum TSH (mIU/L)1.10 (0.66–1.58)0.82 (1.03–2.45)***0.016

[i] P-value by *Independent samples t-test (data are presented as mean ± SD);

[ii] p-value by **Chi-square test (data are presented as count and percent);

[iii] p-value by ***Mann–Whitney U test (data are presented as median and IQR).

Figure 1:

ROC curve analysis of the α-Klotho and γ-Klotho genes for the diagnosis of DTC versus goiter.

Table 2:

Association between the demographics and the clinicopathological parameters and the two groups of the α-Klotho gene expression.

Parameterα-Klotho gene expression (Fold change)p
High (>0.68) (n=5)Low (≤0.68) (n=35)
Age<45years4 (80%)21 (60%)**0.388
45years1 (20%)14 (40%)
Sexmale1 (20%)8 (22.9%)**0.886
female4 (80%)27 (77.1%)
BMI (kg/m2)30.3±5.430.3±6.4*0.988
Tumor size (cm)0.94±0.42.91±0.9*<0.001
LNMabsent3 (60.0%)17 (49.0%)**0.633
present2 (40.0%)18 (51.0%)
Lateral LNMabsent3 (60.0%)22 (62.9%)**0.902
present2 (40.0%)13 (37.1%)
Lymphovascular permeationabsent4 (80.0%)20 (57.1%)**0.631
present1 (20.0%)15 (42.9%)
Lymphocytic infiltrationabsent4 (80.0%)30 (85.7%)**0.738
present1 (20.0%)5 (14.3%)
Extrathyroidal invasionabsent5 (100.0%)27 (77.1%)**0.232
present0 (0.0%)8 (22.9%)
Capsular invasionabsent5 (100.0%)23 (65.7%)**0.298
present0 (0.0%)12 (34.3%)
Multifocalityabsent5 (100.0%)17 (48.6%)**0.031
present0 (0.0%)18 (51.4%)
Pathological typepapillary4 (80.0%)27 (77.1%)**0.525
follicular1 (20.0%)8 (22.9%)
Calcificationabsent3 (60.0%)16 (45.7%)**0.550
present2 (40.0%)19 (54.3%)
Marginill-defined0 (0.0%)15 (42.9%)**0.137
well-defined5 (100.0%)20 (57.1%)
StageI5 (100%)27 (77.1%)**0.699
II0 (0%)3 (8.6%)
III0 (0%)1 (2.9%)
IVA0 (0%)4 (11.4%)

[i] p-value by *Independent samples t-test (data are presented as mean ± SD);

[ii] p-value by **Chi-square test (data are presented as count and percent).

Table 3:

Correlations of the α-Klotho gene expression with γ-Klotho gene expression and with different parameters.

α-Klotho gene expression
ParameterCorrelation coefficientp-value
γ-Klotho gene expression−0.0650.565
Age−0. 2330.037
BMI−0.2100.194
Serum total T30.0840.606
Serum total T40.1010.534
Serum TSH−0.2580.108
Stage−0.3460. 026
Tumor size−0.898<0.001

[i] p-value by Spearman's correlation coefficient test.

Table 4:

Correlations of the γ-Klotho gene expression with different parameters.

γ-Klotho gene expression
ParameterCorrelation coefficientp-value
Age−0.0280.866
BMI−0.2540.114
Serum total T30.1860.250
Serum total T40.2440.130
Serum TSH−0.1560.338
Stage−0.1040.525
Tumor size−0.0890.586

[i] p-value by Spearman's correlation coefficient test.

Table 5:

Logistic regression analysis to predict the likelihood of DTC on top of goiter.

ParameterCrude OR95% CIp-value
BMI0.9980.99–1.0060.626
Serum total T31.0230.83–1.260.831
Serum total T41.0040.97–1.0390.836
Serum TSH1.0630.95–1.190.285
α-Klotho gene expression0.5060.343–0.7460.001
γ-Klotho gene expression1.0590.893–0.1.2560.508

[i] p-value by simple logistic regression analysis (crude OR: crude odds ratio; 95% CI: 95% confidence interval).

Table 6:

Predictors of higher stage of DTC.

PredictorAdjusted OR (95% CI)p-value
Gender (female)2.2395(0.747–7.675)0.142
Serum total T41.220(0.956–1.56)0.110
Serum TSH0.812(0.587–1.125)0.211
α-Klotho gene expression0.671(0.246–0.835)0.037

[i] p-value by multivariate ordinal regression analysis (adjusted OR: adjusted odds ratio; 95% CI: 95% confidence interval).

DOI: https://doi.org/10.2478/fco-2023-0006 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Language: English
Page range: 31 - 39
Submitted on: Dec 15, 2022
Accepted on: Jul 25, 2023
Published on: Sep 15, 2023
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services

© 2023 Wesam S. El-Saeed, Marwa H. Elnagdy, Mahmoud A. Abd elghaffar, Ayman El Baz, Mohammed A. Zahran, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.